title: Optimising daytime deliveries when inducing labour using prostaglandin vaginal inserts.
abstract: OBJECTIVE
  To determine induction start time(s) that would maximise daytime deliveries when using prostaglandin vaginal inserts.
  
  
  METHODS
  Women enrolled into the Phase III trial, EXPEDITE (clinical trial registration: NCT01127581), had labour induced with either a misoprostol or dinoprostone vaginal insert (MVI or DVI). A secondary analysis was conducted to determine the optimal start times for induction by identifying the 12-h period with the highest proportion of deliveries by parity and treatment.
  
  
  RESULTS
  Optimal start times for achieving daytime deliveries when using MVI appear to be 19:00 in nulliparae and 23:00 in multiparae. Applying these start times, the median time of onset of active labour would be approximately 08:30 for both parities and the median time of delivery would be the following day at approximately 16:30 for nulliparae and 12:00 (midday) for multiparae. Optimal start times when using DVI appear to be 07:00 for nulliparae and 23:00 for multiparae. Using these start times, the median time of onset of active labour would be the following day at approximately 04:00 and 11:50, and the median time of delivery would be approximately 13:40 and 16:10, respectively.
  
  
  CONCLUSIONS
  When optimising daytime deliveries, different times to initiate induction of labour may be appropriate depending on parity and the type of retrievable prostaglandin vaginal insert used.
authors.affiliation: a Watching Over Mothers & Babies Foundation , Tucson , AZ , USA .
authors.forename: Hugh
authors.initials: H
authors.lastname: Miller
authors.affiliation: b Department of Obstetrics, Gynecology and Reproductive Sciences , Temple University , Philadelphia , PA , USA .
authors.forename: Laura
authors.initials: L
authors.lastname: Goetzl
authors.affiliation: c Department of Obstetrics and Gynecology , University of California , Irvine, Orange , CA , USA .|d Miller Children's and Women's Hospital , Long Beach , CA , USA .
authors.forename: Deborah A
authors.initials: DA
authors.lastname: Wing
authors.affiliation: e Independent Consultant , Phoenixville , PA , USA , and.
authors.forename: Barbara
authors.initials: B
authors.lastname: Powers
authors.affiliation: f Ferring Pharmaceuticals , Copenhagen , Denmark.
authors.forename: Olof
authors.initials: O
authors.lastname: Rugarn
mesh_terms: D036861:Delivery, Obstetric; D015232:Dinoprostone / Q000008:administration & dosage; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007751:Labor, Induced / Q000379:methods*; D016595:Misoprostol / Q000008:administration & dosage; D010120:Oxytocics / Q000008:administration & dosage*; D010298:Parity; D011247:Pregnancy; D013488:Suppositories; D013997:Time Factors
chemical_list: D010120:Oxytocics; D013488:Suppositories; D016595:Misoprostol; D015232:Dinoprostone
keywords: Daytime deliveries; dinoprostone; induction of labour; misoprostol; retrievable prostaglandin vaginal delivery systems